TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second IV bolus administration

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase® (tenecteplase), a thrombolytic or clot-dissolving agent,

Tenecteplase is administered as a single, 5-second intravenous bolus, providing a faster and simpler option compared to the standard 60-minute infusion of alteplase.

Genentech announced that the U.S. Food and Drug Administration has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, Genentech has had the lone medicine on the market for stroke. On Monday, the Roche subsidiary added a second stroke treatment to its repertoire,

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.